Regent Pacific Group Limited announced that Orient EuroPharma Co. Ltd. the Group's commercial strategic partner for Taiwan, Hong Kong, Macau and some other countries and regions in South East Asia has received the marketing authorisation approval for Taiwan from the Taiwan Food and Drug Administration. This is the final regulatory approval process required for the marketing, distribution and sale of Fortacin, a solution to premature ejaculation, in Taiwan. Pursuant to the licence agreement with Orient EuroPharma, Regent Pacific will receive a payment of $300,000 from Orient EuroPharma.